OATD-02 may demonstrate effectiveness in the treatment of immune-related cancers and in cancers with enhanced ARG2 expression, such as pancreatic cancer, chronic and acute myeloid leukemia, kidney cancer, and in patients with prostate cancer [17,77,127,193,194,195]. Here, ARG2 is linked to kidney cancer.